Visão geral da empresa Acusphere
Biotecnologia e farmacêuticaIndústria
Acusphere micromanages its products, but then how else would you handle microparticles? The company uses a proprietary technology to create porous microparticles smaller than red blood cells to develop cardiovascular drugs for the detection of coronary artery disease. The company is seeking marketing approval for lead injectable candidate Imagify, an injectable drug designed to identify coronary artery disease. Additional candidates in Acusphere's pipeline included treatments for acute pain (AI-525), cancer (AI-850), and asthma (AI-128). However, the company sold AI-525 and AI-850 to Cephalon for about $30 million.
